Therefore, high levels of sustained NRF2 activity, which would occur following KEAP1 loss or mutation but not following pharmacological inhibition of KEAP1, may be required to provide a growth or survival advantage to some cancer cells. This evidence concerns the gene KEAP1 and cancer.